Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Assets (2022 - 2025)

Historic Current Assets for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $338.3 million.

  • Entrada Therapeutics' Current Assets fell 2730.89% to $338.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.3 million, marking a year-over-year decrease of 2730.89%. This contributed to the annual value of $440.0 million for FY2024, which is 1900.31% up from last year.
  • Per Entrada Therapeutics' latest filing, its Current Assets stood at $338.3 million for Q3 2025, which was down 2730.89% from $369.1 million recorded in Q2 2025.
  • Entrada Therapeutics' Current Assets' 5-year high stood at $489.5 million during Q2 2024, with a 5-year trough of $209.9 million in Q4 2022.
  • Its 4-year average for Current Assets is $364.5 million, with a median of $383.0 million in 2023.
  • Per our database at Business Quant, Entrada Therapeutics' Current Assets surged by 7618.63% in 2023 and then crashed by 2730.89% in 2025.
  • Entrada Therapeutics' Current Assets (Quarter) stood at $209.9 million in 2022, then surged by 76.19% to $369.8 million in 2023, then rose by 19.0% to $440.0 million in 2024, then decreased by 23.13% to $338.3 million in 2025.
  • Its Current Assets was $338.3 million in Q3 2025, compared to $369.1 million in Q2 2025 and $403.2 million in Q1 2025.